MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Senti Biosciences, Inc. (NASDAQ:SNTI)*
Organization & Developments: Senti Biosciences
Parents
Senti Biosciences, Inc. (NASDAQ:SNTI)*
Children
*Develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
*Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
*Senti (SNT) has developed a suite of technologies including logicgates, calibrated-release cytokines, small-molecule regulated promoters....[that] can be used independently or in concert to achieve an optimized therapeutic profile across multiple modalities including various engineered cell therapy types as well as viral vectors
*Senti has two candidates based on donor-derived CAR-NK cells: SENTI-202 for acute myeloid leukemia, and SENTI-301 for hepatocellular carcinoma.
2022: Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform_seekingalpha.com
2024: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
2025: Off-the-shelf CAR Natural Killer Cell Therapy with Logic Gates Elicits Complete Remissions in Relapsed or Refractory Blood Cancers
Jumps
Finance & Acquisitions: Senti Biosciences
Key People: Senti Biosciences